Company research
Tempus AI, Inc.
CIK 1717115Updated Sep 26, 2026
SecurityTEM · NASDAQ · equity
Name history
Tempus Labs, Inc. · through Dec 5, 2023
TEM price & chart
Loading TradingView…
NASDAQ:TEM on TradingView ↗About the company
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
In the news
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus ↗
The Future of Intoxication Detection May Be in Your Voice ↗
TEM Securities Lawsuit Filed Against Tempus AI, Inc. Contact the DJS Law Group to Discuss Your Rights News provided by DJS Law Group LLP Aug 12, 2025, 04:41 ET Share this article Share to X Share this article Share to X LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- The DJS Law Group reminds investor ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 2,274,838,000Source | 926,116,000Source | 564,052,000Source |
| Property, Plant and Equipment, NetUSD | 89,156,000Source | 58,056,000Source | 61,681,000Source |
| GoodwillUSD | 470,211,000Source | 73,343,000Source | 73,354,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 355,253,000Source | 11,716,000Source | 21,916,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 604,787,000Source | 340,954,000Source | 165,767,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 311,170,000Source | 154,819,000Source | 94,462,000Source |
| Inventory, NetUSD | 51,724,000Source | 38,386,000Source | 28,845,000Source |
| Assets, CurrentUSD | 1,167,175,000Source | 667,603,000Source | 350,331,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 40,498,000Source | 26,135,000Source | 17,295,000Source |
| Operating Lease, Right-of-Use AssetUSD | 64,496,000Source | 14,762,000Source | 20,530,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 1,783,512,000Source | 869,777,000Source | 840,672,000Source |
| Stockholders’ equity: | |||
| Retained Earnings (Accumulated Deficit)USD | -2,395,862,000Source | -2,150,834,000Source | -1,396,917,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 902,000Source | 94,000Source | 5,000Source |
| Stockholders' Equity Attributable to ParentUSD | 491,326,000Source | 56,339,000Source | -1,382,163,000Source |
| Additional Paid in Capital, Common StockUSD | 2,892,910,000Source | 2,210,664,000Source | 18,345,000Source |
| Liabilities and EquityUSD | 2,274,838,000Source | 926,116,000Source | 564,052,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 372,388,000Source | 291,070,000Source | 232,627,000Source |
| Operating Lease, Liability, CurrentUSD | 13,355,000Source | 6,459,000Source | 6,437,000Source |
| Accounts Payable, CurrentUSD | 81,994,000Source | 53,804,000Source | 54,421,000Source |
| Operating Lease, Liability, NoncurrentUSD | 74,272,000Source | 26,199,000Source | 32,040,000Source |
| Other Liabilities, NoncurrentUSD | 56,600,000Source | 15,980,000Source | 19,751,000Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 155,370,000Source | 130,407,000Source | 82,517,000Source |
| Deferred Tax Liabilities, NetUSD | 330,000Source | 234,000Source | 123,000Source |
| Dividends Payable, CurrentUSD | — | 0Source | 9,797,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 124,747,000Source | 534,138,000Source | 0Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | 90,402,000Source | 61,037,000Source | 7,347,000Source |
| Increase (Decrease) in InventoriesUSD | 3,369,000Source | 9,541,000Source | 6,563,000Source |
| Increase (Decrease) in Accounts PayableUSD | -7,241,000Source | -23,852,000Source | -23,363,000Source |
| Deferred Income Tax Expense (Benefit)USD | -52,665,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -218,090,000Source | -189,045,000Source | -214,339,000Source |
| Cash flows from investing activities: | |||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 376,666,000Source | 0Source | 5,705,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -398,355,000Source | -130,392,000Source | -40,313,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 21,049,000Source | 22,121,000Source | 34,608,000Source |
| Cash flows from financing activities: | |||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 0Source | 69,918,000Source | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 884,123,000Source | 494,329,000Source | 117,547,000Source |
| Dividends paid | — | — | — |
| Repayments of Long-term DebtUSD | 276,892,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 267,616,000Source | 175,228,000Source | -137,124,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 609,451,000Source | 341,835,000Source | 166,607,000Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 44,031,000Source | 28,045,000Source | 16,913,000Source |
| Income Taxes Paid, NetUSD | 654,000Source | 206,000Source | 161,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -62,000Source | 336,000Source | -19,000Source |
| Additional Financial Items | |||
| Accretion ExpenseUSD | 268,000Source | 197,000Source | 90,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 124,747,000Source | 534,138,000Source | 0Source |
| Amortization of Debt Issuance CostsUSD | 484,000Source | 510,000Source | 510,000Source |
| DepreciationUSD | 32,054,000Source | 26,356,000Source | 21,279,000Source |
| Depreciation, NonproductionUSD | 16,307,000Source | 12,218,000Source | 8,318,000Source |
| Dividends Payable, CurrentUSD | — | 0Source | 9,797,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | 16,471,000Source | 12,110,000Source | 9,807,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | 3,264,000Source | 6,081,000Source | 0Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 13,207,000Source | 6,030,000Source | 9,807,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -415,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | -12,034,000Source | — | — |
| GoodwillUSD | 470,211,000Source | 73,343,000Source | 73,354,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 0Source | 7,359,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | -5,614,000Source | -4,228,000Source | -301,000Source |
| Income Tax Expense (Benefit)USD | -51,684,000Source | 266,000Source | 288,000Source |
| Investment Income, InterestUSD | 12,628,000Source | 11,084,000Source | 7,601,000Source |
| Net Income (Loss) Attributable to ParentUSD | -245,028,000Source | -705,809,000Source | -214,118,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -245,028,000Source | -746,330,000Source | -265,964,000Source |
| Other Nonoperating Income (Expense)USD | 31,447,000Source | 32,336,000Source | 21,822,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 1,271,789,000Source | 693,398,000Source | 531,822,000Source |
| Selling, General and Administrative ExpenseUSD | 731,738,000Source | 755,351,000Source | 296,760,000Source |
| Operating Income (Loss)USD | -252,872,000Source | -691,082,000Source | -196,083,000Source |
| Other Nonoperating Income (Expense)USD | 31,447,000Source | 32,336,000Source | 21,822,000Source |
| Income Tax Expense (Benefit)USD | -51,684,000Source | 266,000Source | 288,000Source |
| Net Income (Loss) Attributable to ParentUSD | -245,028,000Source | -705,809,000Source | -214,118,000Source |
| Earnings Per Share, BasicUSD per share | -1.41Source | -6.23Source | -4.2Source |
| Earnings Per Share, DilutedUSD per share | -1.41Source | -6.23Source | -4.2Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 174,264Source | 119,849Source | 63,306Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 174,264Source | 119,849Source | 63,306Source |
| Additional Financial Items | |||
| Costs and ExpensesUSD | 1,524,661,000Source | 1,384,480,000Source | 727,905,000Source |
| Current Income Tax Expense (Benefit)USD | 885,000Source | 155,000Source | 165,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | 3,264,000Source | 6,081,000Source | 0Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -290,382,000Source | -701,648,000Source | -213,522,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | -5,614,000Source | -4,228,000Source | -301,000Source |
| Interest Expense, DebtUSD | 70,267,000Source | 53,653,000Source | 46,869,000Source |
| Investment Income, InterestUSD | 12,628,000Source | 11,084,000Source | 7,601,000Source |
| Labor and Related ExpenseUSD | 276,208,000Source | 162,194,000Source | 135,466,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -245,028,000Source | -746,330,000Source | -265,964,000Source |
| Research and Development ExpenseUSD | 172,924,000Source | 149,325,000Source | 90,343,000Source |
Filing attachments
tem-ex99_1.htm · 8-K · 2026-07-30
EX-99.1 2 tem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempus Reports Second Quarter 2026 Results CHICAGO, July 30, 2026 - Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026. “Q2 was another exceptional quarter for us,” said Eric Lefkofsky, Founder and CEO of Tempus. “Our strategy is working given the investments we have made in AI over the past several years are…
Read attachment ↗d124162dex991.htm · 8-K · 2026-07-20
EX-99.1 2 d124162dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the cancer care continuum and accelerates access to industry-leading technology with…
Read attachment ↗d117982dex41.htm · 8-K · 2026-05-13
EX-4.1 2 d117982dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 Execution Version TEMPUS AI, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 12, 2026 0.00% Convertible Senior Notes due 2032 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section …
Read attachment ↗d117982dex42.htm · 8-K · 2026-05-13
EX-4.2 3 d117982dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT HEREUNDER IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUE…
Read attachment ↗d117982dex991.htm · 8-K · 2026-05-13
EX-99.1 5 d117982dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense Proceeds expected to be used to repay in full outstanding loans under the senior secured credit facilities, reducing interest expense and enhancing financial flexibility. Additional proceeds expected to be used to pay for capped call transactions to reduce potential dilution and for general corporate pu…
Read attachment ↗d117982dex992.htm · 8-K · 2026-05-13
EX-99.2 6 d117982dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes CHICAGO - (BUSINESS WIRE)-May 8, 2026 - Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $400.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”) in a private placement (the “Offerin…
Read attachment ↗